Home / Companies / TEVA / Catalysts / Page 2 Catalysts · TEVA · CIK 818686 · page 2 of 2 TEVA catalysts and FDA events, page 2. Updated November 16, 2026 Snapshot 20261116T222116Z Built 2026-11-16 22:21 UTC
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on TEVA PDUFA dates and upcoming catalysts . This page continues the list.
Past catalysts and FDA decisions (continued) Date Drug Company Event Indication Status Source October 22, 2024 SELARSDI TEVA FDA approval — Approved SEC 8-K Exhibit 99.1 Jul 2024Month disclosed AUSTEDO (deutetrabenazine) TEVA FDA approval — Approved SEC 8-K Exhibit 99.1 May 2024Month disclosed AUSTEDO (deutetrabenazine) TEVA FDA approval — Approved SEC 8-K Exhibit 99.1 April 16, 2024 WEZLANA® (ustekinumab) TEVA FDA approval — Approved SEC 8-K Exhibit 99.1 February 24, 2024 AMJEVITA® (adalimumab) TEVA FDA approval — Approved SEC 8-K Exhibit 99.1 February 24, 2024 SIMLANDI® TEVA FDA approval — Approved SEC 8-K Exhibit 99.1 November 29, 2023 Alvaiz (eltrombopag choline) TEVA FDA approval — Approved openFDA Drugs@FDA November 21, 2023 TAXOL® (paclitaxel) TEVA Label expansion — Approved openFDA Drugs@FDA May 11, 2023 TAXOL® (paclitaxel) TEVA FDA approval — Approved openFDA Drugs@FDA April 28, 2023 UZEDY (risperidone) TEVA FDA approval schizophrenia in adults Approved SEC 8-K Exhibit 99.1 February 17, 2023 AUSTEDO (deutetrabenazine) TEVA FDA approval — Approved SEC 8-K Exhibit 99.1 April 15, 2022 UZEDY (risperidone) TEVA Complete Response Letter — CRL issued FDA Complete Response Letters July 30, 2021 Micafungin In Sodium Chloride 0.9% (micafungin sodium) TEVA FDA approval — Approved openFDA Drugs@FDA July 9, 2021 Airduo Digihaler (fluticasone propionate; salmeterol xinafoate) TEVA Label expansion — Approved openFDA Drugs@FDA July 9, 2021 Armonair Respiclick (fluticasone propionate) TEVA Label expansion — Approved openFDA Drugs@FDA June 24, 2021 AUSTEDO (deutetrabenazine) TEVA Label expansion — Approved openFDA Drugs@FDA March 13, 2020 Romidepsin (romidepsin) TEVA FDA approval — Approved openFDA Drugs@FDA January 27, 2020 Ajovy (fremanezumab-vfrm) TEVA Label expansion — Approved openFDA Drugs@FDA September 5, 2019 Fosaprepitant Dimeglumine (fosaprepitant dimeglumine) TEVA FDA approval — Approved openFDA Drugs@FDA September 14, 2018 Ajovy (fremanezumab-vfrm) TEVA FDA approval — Approved openFDA Drugs@FDA September 7, 2018 Cassipa (buprenorphine hydrochloride; naloxone hydrochloride) TEVA FDA approval — Approved openFDA Drugs@FDA October 26, 2017 Faslodex (fulvestrant) TEVA Complete Response Letter — CRL issued FDA Complete Response Letters August 30, 2017 AUSTEDO (deutetrabenazine) TEVA FDA approval — Approved openFDA Drugs@FDA June 2, 2017 Romidepsin (romidepsin) TEVA Complete Response Letter — CRL issued FDA Complete Response Letters April 3, 2017 AUSTEDO (deutetrabenazine) TEVA FDA approval — Approved openFDA Drugs@FDA January 27, 2017 Airduo Digihaler (fluticasone propionate; salmeterol xinafoate) TEVA FDA approval — Approved openFDA Drugs@FDA January 27, 2017 Armonair Respiclick (fluticasone propionate) TEVA FDA approval — Approved openFDA Drugs@FDA January 17, 2017 Vantrela Er (hydrocodone bitartrate) TEVA FDA approval — Approved openFDA Drugs@FDA September 30, 2016 Cassipa (buprenorphine hydrochloride; naloxone hydrochloride) TEVA Complete Response Letter — CRL issued FDA Complete Response Letters June 1, 2016 Romidepsin (romidepsin) TEVA Complete Response Letter — CRL issued FDA Complete Response Letters May 27, 2016 AUSTEDO (deutetrabenazine) TEVA Complete Response Letter — CRL issued FDA Complete Response Letters March 23, 2016 Cinqair (reslizumab) TEVA FDA approval — Approved openFDA Drugs@FDA February 28, 2011 Milprosa (progesterone) TEVA Complete Response Letter — CRL issued FDA Complete Response Letters
FDA calendar PDUFA dates PDUFA calendar AdCom calendar FDA approvals today CRL tracker PDUFA outcomes dataset Indications Every catalyst is quoted from TEVA’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.